Navigation Links
John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
Date:12/7/2010
eclinical activity against leukemia, lymphoma, and myeloma, and clinical activity against treatment-resistant cancers in early-stage human trials.
Fifty-seven patients with a median age of 72 years old (range 46-85) were enrolled in the current study. Patients received 21-day cycles of MLN8237 (50 mg) for seven days followed by 14 days rest until disease progression or unacceptable toxicity. Forty-six (81%) patients had AML, of whom 21 (37%) had secondary leukemia, while 11 (19%) patients had MDS.
Dr. Goldberg and colleagues concluded MLN8237 has anti-leukemia activity with a 13% response rate (all AML) with advanced, mainly pre-treated disease.
"We found that patients for with rapidly progressive disease, improved outcomes require strategies to enhance both disease control and risk management in early cycles, allowing time needed to achieve clinical benefit from AAK inhibition," said Dr. Goldberg. "Our results support further clinical studies of MLN8237 in heme-lymphatic malignancies and solid tumors."
The Eastern Cooperative Oncology Group, one of the largest clinical cancer research organizations in the United States, previously reported superior one and two-year survival for newly diagnosed symptomatic multiple myeloma patients initially treated with lenalidomide plus low-dose dexamethasone, versus those treated with lenalidomide plus high-dose dexamethasone. As a result of this analysis, lenalidomide plus low-dose dexamethasone is now considered the standard of care.
In this multicenter trial, lead author David Vesole, MD, PhD, FACP, Co- Chief and Director of Research, Multiple Myeloma, John Theurer Cancer Center and colleagues evaluated the impact of age on dexamethasone dose intensity and overall survival.
The study randomly assigned 445 to patients to LD (233 patients) or Ld (222 patients) treatment groups and analyzed data for all enrolled patients ("intent-to-treat" analysis) for overall sur
'/>"/>
| Contact: Amy Leahing amy.leahing@gmail.com 305-458-0599 John Theurer Cancer Center Source:Eurekalert |
Related medicine news :
1. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
2. John Theurer Cancer Center to present innovative research at 2 surgical meetings
3. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
4. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
5. The John Theurer Cancer Center recognizes medical physics team for safety track record
6. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
7. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
8. John Theurer Cancer Center offers breakthrough radiation measurement technology
9. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
10. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
11. Daily Aspirin Linked to Steep Drop in Cancer Risk
Post Your Comments:
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... the rights of victims injured by defective medical devices, is ... in the case of the Estate of Fred E. Taylor ... County (Port Orchard). A May 21, 2013, Bloomberg ... Surgical had acted like a “car dealership” in how it ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
(Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...
(Date:5/21/2013)... 2013 The federal judge overseeing the ... lawsuits in U.S. District Court, Northern District of ... request from Plaintiffs’ Counsel to conduct Ex Parte interviews ... 17th Order grants that request, and sets forth procedures ... Wright Medical Technology, Inc., Conserve Hip Implant Products Liability ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3[0] Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership[0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants[0] Post-approval TAVI registry shows high rates of device success at 1 year[0] Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation[0] Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island
... brain,s dopamine levels could point to more effective treatments ... -- Long-term changes in the brain,s dopamine-releasing machinery may ... say. , Dopamine is one of the brain,s major ... Bamford, of the University of Washington, Seattle, treated mice ...
... Skin Care and Frida,Kahlo Store are proud to announce the ... benefit of The Leukemia & Lymphoma Society. It,will take place ... Staten Island, New York, at 7:30 pm. This concert is ... with the solution,of health and social problems., The event ...
... leading global clinical,research organization, is pleased to announce that ... with CRO,s in Las Vegas, Nevada from April,14 to ... by,some of its executive team and employees. Chiltern will ... 2008 at 2:45 pm -- Track: Relationship Management ...
... to use iSEEK Medical Searchblade to optimize patient management ... ... 9 Physicians, nurses,physician assistants, pharmacists, and other clinicians searching for,medical ... Thanks to a new partnership between MedPage Today and iSEEK,the medical ...
... Peninsula Medical School, South West England, has found strong ... health of older people. , Two studies were conducted, ... Study of Ageing (ELSA). , The first study ... lived in urban areas across England. The study found ...
... April 9, 2008 Reflecting the,growing concern over ... in being able to afford a comfortable retirement,decreased ... in the 18 years of the,Retirement Confidence Survey(R)(RCS), ... of workers very confident about having enough money ...
Cached Medicine News:Health News:Researchers Define Mechanism of Methamphetamine Addiction 2Health News:Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008. 2Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 2Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 3Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 4Health News:Your neighborhood can affect your health 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 3Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 4Researchers Define Mechanism of Methamphetamine AddictionFrida Kahlo - Passion for Life CONCERT GALA 2008Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008.MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient CareYour neighborhood can affect your health18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ... Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine[0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference[0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market
... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...
... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009. Gross profit was ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Transgenomic Reports Fourth Quarter Financial Results 2Transgenomic Reports Fourth Quarter Financial Results 3Transgenomic Reports Fourth Quarter Financial Results 4Transgenomic Reports Fourth Quarter Financial Results 5Transgenomic Reports Fourth Quarter Financial Results 6Transgenomic Reports Fourth Quarter Financial Results 7Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B2 Biological Safety Cabinet...
Class II Type A2 Biological Safety Cabinet...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |